GlucoDYNAMIX™ Diabetes Interventions; Over 125,000 Served
Automated Diabetes Technology Delivers Over 125,000 Interventions With Demonstrated Improvements in Clinical Outcomes & Cost Savings
Dallas, TX (PRWEB) November 29, 2006
Diabetech®'s GlucoDYNAMIX diabetes intervention system raises the bar for interventional healthcare. GlucoDYNAMIX intelligent interventions have evolved over the past 5 years based on experience from over a dozen clinical trials with input from leading physicians, endocrinologists, behavioral psychologists, medical informatics researchers, people with diabetes and their extended care teams.
"GlucoDYNAMIX represents an entirely new category of healthcare information technology," says Kevin McMahon, President & CEO of Diabetech. "Looking across the board at pharma trials, clinical management and patient self-management, virtually everything out there is just now talking about moving to web-based data distribution versus the cumbersome cabled PC application. The key to enabling desperately needed improved outcomes isn't merely changing the location of stored patient data from the medical device to the PC or on the Web. Rather, it's about empowering patients, their social networks and simultaneously increasing the caring capacity and effectiveness of an overworked and inefficient healthcare system.
Interventions are delivered using any number of software interfaces including web, email, imaging, text messaging, ambient displays, telephone and more. More importantly, only Diabetech has the clinical trials experience across all different types of patients to understand not only when and how but also when not to intervene. The result is a 98% satisfaction rating from our trial participants including patients, caregivers and members of the medical team.
The platform is based on a sophisticated real-time wireline & wireless gateway. In this way, data from multiple medical devices is collected on the fly, as the data is created. In turn, the remote system analyzes each data point as well as trends in the patient record and determines the best time to intervene.
Diabetech is presently developing its 510(k) application for the GlucoDYNAMIX software system and plans to submit to the FDA in Q1 2007. We anticipate receiving marketing clearance around the middle of next year opening the doors to large-scale commercial expansion of several recent clinical trials. Based on the data collected so far, we plan to seek indications that correlate to the significant drops witnessed in trial participant's average blood glucose levels (as measured by the A1c test), decreased frequency of severe hypoglycemia and minimized extended excursions of hyperglycemia.
This service offering is compliant with applicable federal and state regulations including HIPAA, which govern the privacy and security of human subjects research. For more information please call 877.My. Gluco or send email to info @ diabetech. net.
About Diabetech
Diabetech, with its healthcordia™ and diabetes house call™ programs, leads the world with more interventions served than any other diabetes program provider. A Dallas, Texas based manufacturer of wireless medical devices, diabetes supplies and service provider infrastructure, we push the limits of clinical informatics in the delivery of real-world diabetes care. For more information on the company and to participate in our version of proactive care, please visit www. diabetech. net
Diabetech and GlucoMON are registered trademarks of Diabetech, LP. Healthcordia, Diabetes House Call and GlucoDYNAMIX are trademarks of Diabetech, LP. All other trademarks are the property of their registered owners.
###
